1.Value of Preoperative Imaging Localization With the ~(99)Tc~m-MIBI Imaging for Primary Hyperparathyroidism
Shiyun LI ; Ruqi DAI ; Xueshu LIU
Journal of Chinese Physician 2000;0(11):-
0 05).Conclusions Double phase 99 Tc m-MIBI imaging is a promising technique for localization of parathyroid adenomas. We consider that the patients should undergo the noninvasive imaging procedures before their initial neck exploration.
2.Analysis of ~(99m)TcO_4 Imaging Parameters of Hyperthyroidism
Ruqi DAI ; Shiyun LI ; Xueshu LIU
Journal of Chinese Physician 2001;0(08):-
Objective To investigate the radionuclide 99m TcO 4 imaging parameters of thyroid in hyperthyroid patients. Methods 200 patients with hyperthyroidism including 153 women and 47 men received radionuclide 99m TcO 4 plane scintigraphy for thyroid. Then the size and anatomic configuration of thyroid, tracer distribution, and the pyramid lobe appearance were analyzed.Results 400 images of thyroid lobes were obtained from 200 patients. The length of single thyroid lobe in 169 patients were between 5cm and 7cm, in 33 patients exceeded 7cm, and in 38 patients was less than 5cm. The width of single thyroid lobe in 144 patients were between 2.5cm and 3.5cm, in 6 patients exceeded 3.5cm, and in 85 patients ware less than 3.5cm. 61% of patients had the widened narrow part of thyroid. The tracer evenly distributed in most patients, and small multinodular thyroid and single nodular thyroid were found only in 9.0% and 3.2% patients respectively. Pyramid lobe appeared in 12 patients.Conclusion SPECT imaging paremeters of the thyroids in hyperthyroid patients mainly were a diffuse goiter with the widened narrow part of thyroid and without nodule and pyramid lobe.
3.Treatment of keloid with self-made 32P applicator
Ruqi DAI ; Wenjian YOU ; Shiyun LI ; Huan XIAO
Chinese Journal of Tissue Engineering Research 2009;13(28):5597-5600
OBJECTIVE: To investigate the clinical efficacy of self-made 32P applicator for treating different kinds of keloid. others were treated with surgical excision combined with self-made 32P applicator. The 32P applicator was shaped according to the size and shape of the diseased region and the application time was calculated according to the dose rate and the decay correction. 4.0-5.0 Gy was applied in every diseased region in each of the four days (one course), and 4-6 courses in total was required, with 4 weeks of intervals following each course. For children, dose was reduced to 4 Gy or less once a day in every diseased region. Patients in the operation combined with application group were performed keloids excision first. Then 32P applicators were applied to the wound without any exudation in the same way as above. RESULTS: Of all the 39 patients (lesion thickness≤0.3 cm, 32P applicator therapy only), 32 ones was cured (82.1%), with the total effective rate of 98%. For patients with lesion thickness > 0.3 cm, the total effective rate of 32P applicator therapy and surgical excision combined with self-made 32P applicator were 55.6% and 93.3% respectively, and the difference was ofsignificance (P < 0.01 ). Among these patients, those with disease course less than 9 months had the effective rates of 25.0% and75.0% corresponding to 32P applicator therapy only and surgical excision combined with self-made 32p applicator respectively.For those with long course of disease, the effective rates were 13% and 77% respectively. A total of 26 patients experienced local buming and slight pain during the 32P applicator treatment, and all the symptoms were relieved by using calamine lotion; 5 patients and 2 patients expedencad grade Ⅰ and Ⅱ radio dermatitis respectively, which were relieved by using Mupirocin Ointment. No radio dermatitis of grade Ⅲ or above occurred to any patient. In addition, pigmentation or color changing occurred at local skins of cured patients.CONCLUSION: 32P applicator therapy is safe and effective for treating keloid. For patients with short disease course and lesion thickness ≤0.3 cm, 32P applicator therapy only is enough. Otherwise, patients are suggested to use 32P applicator after operation.
4.Application analysis of time-resolved fluorescence immunoassay technology in syphilis specific antibody screening
Wei DAI ; Shiyun LI ; Dejun XIAO ; Ting LIU ; Jiuchang XIAO ; Jing LI
International Journal of Laboratory Medicine 2015;(21):3117-3118
Objective To investigate the application of time‐resolved fluorescence immunoassay (TRFIA) in the detection of specific antibody of syphilis .Methods Specific antibody of syphilis was detected in serum samples of 240 cases of syphilis and 150 healthy subjects by TRFIA ,Treponemal pallidum particle agglutination(TPPA) and Treponemal pallidum enzyme linked immu‐nosorbent assay(TP‐ELISA) .The sensitivity ,specificity and positivity of these three methods were compared .Results The sensi‐tivity of TRFIA ,TP‐ELISA ,TPPA were 100 .00% ,98 .75% and 97 .92% ,without significantly differences(P>0 .05) ,and the spe‐cificity were 99 .33% ,98 .67% and 100 .00% .The false positive rate of TRFIA was 0 .67% ,and the false negative rate was 0 .00% . The false positive rate of TP‐ELISA was 1 .33% ,and the false negative rate was 1 .25% .False positive rate and false negative rate of TRFIA were lower than TP‐ELISA(P<0 .05) .Conclusion TRFIA could be with high sensitivity and specificity in syphilis spe‐cific antibody test ,and could be used for routine screening of syphilis specific antibody .
6.Efficacy and tolerability of dolutegravir plus lamivudine as a switch simplified strategy in treatment-experienced human immunodeficiency virus/acquired immunodeficiency syndrome patients
Shiyun LYU ; Sen WANG ; Wei HUA ; An LIU ; Zaicun LI ; Ying SHAO ; Jiangzhu YE ; Lijun SUN ; Lili DAI
Chinese Journal of Infectious Diseases 2022;40(9):527-532
Objective:To evaluate the efficacy and tolerability of the dual therapy of dolutegravir (DTG) plus lamivudine (3TC) as a switch simplified strategy in treatment-experienced human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) patients.Methods:Treatment-experienced HIV/AIDS patients who switched to a dual therapy containing DTG (50 mg, once daily) plus 3TC (300 mg, once daily) were included in Beijing You′an Hospital, Capital Medical University from September 2016 to May 2019. HIV RNA, CD4 + T lymphocyte count, blood lipid indexes, renal function indexes were collected when patients changed the treatment regimen (baseline) and after 48 weeks of treatment. Efficacy (HIV RNA<50 copies/mL) and safety of the dual therapy were analyzed. Statistical comparisons were performed using the Wilcoxon matched-pairs signed rank test. Results:The reasons for 33 patients switching the treatment regimen were virologic failure (four cases, 12.1%), simplification of regimen (11 cases, 33.3%), and drug toxicity (18 cases, 54.5%). The patients were treated with anti-retroviral therapy (ART) for 2.13 (1.05, 4.23) years before regimens switching. Twenty-nine (87.9%) patients were virologically suppressed at baseline, and four (12.1%) patients were virological failure. After switching to DTG plus 3TC, all 33 patients showed HIV RNA<50 copies/mL after 48 weeks of treatment. The baseline CD4 + T lymphocyte count was 543 (363, 595)/μL. After switching the treatment regimens for 48 weeks, CD4 + T lymphocyte count was significantly increased to 625 (455, 651)/μL, and the difference was statistically significant ( Z=3.14, P=0.002). Compared with baseline, low-density lipoprotein-cholesterol was increased after 48 weeks of treatment (2.35(1.80, 3.08) mmol/L vs 3.12(2.74, 3.87) mmol/L), while triglyceride (2.21(1.27, 4.37) mmol/L vs 1.61(1.20, 2.22) mmol/L), the ratio of total cholesterol to high-density lipoprotein-cholesterol (5.02 (4.13, 6.40) vs 4.70 (3.55, 5.35)) and estimated glomerular filtration rate (106.4(78.2, 118.2) mL/(min·1.73 m 2) vs 88.6 (75.7, 107.9) mL/(min·1.73 m 2)) were decreased. The differences were all statistically significant ( Z=4.89, 2.37, 2.09 and 2.83, respectively, all P<0.050). No patient discontinued due to adverse events. Conclusions:The use of dual therapy containing DTG and 3TC is effective and well-tolerated in treatment-experienced HIV/AIDS patients under any prior ART without significant adverse events.
7.The formula of ω-3 polyunsaturated fatty acids improving cognitive impairment in patients with depres-sion:a clinical randomized double-blind controlled trial
Rong MA ; Shiyun WU ; Cai SONG ; Xu DAI ; Yong-Ping ZHANG ; Hebin HUANG ; Weicong LU ; Runhua WANG ; Guiyun XU ; Kangguang LIN
Chinese Journal of Nervous and Mental Diseases 2023;49(10):591-597
Objective To investigate the effects of different ratios of ω-3 polyunsaturated fatty acids(ω-3 PUFA)on depression and cognitive impairment in patients with major depression.Methods A randomized,double-blinded controlled trial was used to randomly assign patients with depression to a cognitive improvement group,a depression improvement group,and a placebo group.The cognitive improvement group took 1388 mg of docosahexaenoic acid(DHA)and 692 mg of eicosapentaenoic acid(EPA)every day and the depression improvement group took 1248 mg of EPA and 832 mg of DHA every day.The placebo group took the same dose of soybean oil for 12 weeks,during which psychiatric medication was maintained.The 24-item Hamilton depression scale(HAMD-24)was used to evaluate depressive symptoms,and the standardized MATRICS consensus cognitive battery(MCCB)was used to evaluate cognitive function after 6 weeks and 12 weeks,respectively.Results The study recruited a total of 46 patients with depression including 22 in the cognitive improvement group,12 in the depression improvement group,and 12 in the placebo group.After 6 weeks of treatment,the HAMD-24 scores were significantly lower in the depression improvement group(19.00±10.70)and cognitive improvement group(16.58±9.39)than in the placebo group(31.10±10.03)(P<0.01).After 12 weeks of treatment,HAMD-24 scores were significantly lower in the depression improvement group(13.58±8.43)than in the placebo group(28.10±15.04)(P=0.02).No significant interaction effect was found on the cognitive assessment scores in any dimension after 6 weeks and 12 weeks of treatment(P>0.05).The incidence rate of adverse events in the depression improvement group was 16.7%(2/12),and no adverse events were reported in the other two groups.There was no significant difference in the incidence of adverse events among the three groups(P=0.13).Conclusion Treatment with ω-3PUFA for 6 weeks can improve the depressive symptoms of patients with depression.The formula with a higher ratio of EPA exhibits higher effectiveness while the two groups of ω-3PUFA formulas with different ratios do not improve cognitive function.
8.Gestational dexamethasone exposure impacts hippocampal excitatory synaptic transmission and learning and memory function with transgenerational effects.
Mingcui LUO ; Yiwen YI ; Songqiang HUANG ; Shiyun DAI ; Lulu XIE ; Kexin LIU ; Shuai ZHANG ; Tao JIANG ; Tingting WANG ; Baozhen YAO ; Hui WANG ; Dan XU
Acta Pharmaceutica Sinica B 2023;13(9):3708-3727
The formation of learning and memory is regulated by synaptic plasticity in hippocampal neurons. Here we explored how gestational exposure to dexamethasone, a synthetic glucocorticoid commonly used in clinical practice, has lasting effects on offspring's learning and memory. Adult offspring rats of prenatal dexamethasone exposure (PDE) displayed significant impairments in novelty recognition and spatial learning memory, with some phenotypes maintained transgenerationally. PDE impaired synaptic transmission of hippocampal excitatory neurons in offspring of F1 to F3 generations, and abnormalities of neurotransmitters and receptors would impair synaptic plasticity and lead to impaired learning and memory, but these changes failed to carry over to offspring of F5 and F7 generations. Mechanistically, altered hippocampal miR-133a-3p-SIRT1-CDK5-NR2B signaling axis in PDE multigeneration caused inhibition of excitatory synaptic transmission, which might be related to oocyte-specific high expression and transmission of miR-133a-3p. Together, PDE affects hippocampal excitatory synaptic transmission, with lasting consequences across generations, and CDK5 in offspring's peripheral blood might be used as an early-warning marker for fetal-originated learning and memory impairment.